Developer docs
API playgroundTry for free, no card

Search company profiles

Lantheus Holdings

Full company profile

uuid0003vpb

Namestring
Lantheus Holdings
Legal namestring
Lantheus Holdings, Inc.
Websiteurl
lantheus.com
Company typeenum
Public
Founded yearint
1956
Descriptiontext

Lantheus Holdings is a Bedford, Massachusetts-based radiopharmaceutical company that develops, manufactures, and commercializes diagnostic imaging agents and therapeutic radiopharmaceuticals. Founded in 1956 (originally as New England Nuclear Corporation), the company is publicly traded on NASDAQ under the ticker LNTH and operates with over 1,000 employees across the U.S., Canada, Germany, Sweden, Switzerland, and the U.K. Its core technology combines radioactive isotopes with targeting molecules to produce PET and SPECT imaging agents, as well as Lu-177-based therapeutic radiopharmaceuticals.

The commercial portfolio centers on PYLARIFY (piflufolastat F 18), the leading PSMA PET imaging agent for prostate cancer in the U.S. (generating over $240 million in Q4 2025 revenue), and DEFINITY, an ultrasound contrast agent for echocardiography. The pipeline includes the newly approved PYLARIFY TruVu (higher-throughput reformulation), PNT2003 (Lutetium Lu 177 Dotatate for GEP-NETs, tentative FDA approval), MK-6240 (Tau PET for Alzheimer's, August 2026 PDUFA), LNTH-2501/OCTEVY (Ga 68 edotreotide for neuroendocrine tumors, currently subject to an FDA Complete Response Letter), and LNTH-2513/18F-GP1 (DVT imaging). The company has built an integrated theranostics platform spanning diagnostic imaging and therapeutic radiopharmaceuticals, supplemented by AI-enabled image analysis tools (PYLARIFY AI, CURE8) and a CDMO business acquired through Evergreen Theragnostics.

Revenue is generated primarily through one-time product sales of FDA-approved diagnostic and therapeutic radiopharmaceuticals to hospitals, imaging centers, and healthcare providers, distributed via direct sales, an e-commerce portal, and international distributors. The company also derives revenue from Pharma Solutions partnerships providing clinical trial manufacturing support to pharmaceutical companies. In 2026 the company is weighing an unsolicited ~$7 billion takeover offer from Curium Pharma while operating under Interim CEO Mary Anne Heino following the end-of-2025 retirement of CEO Brian Markison and departure of President Paul Blanchfield.

Short descriptiontext

Lantheus Holdings is a publicly traded radiopharmaceutical company that develops and commercializes diagnostic imaging agents and therapeutic radiopharmaceuticals for oncology, neurology, and cardiology, serving hospitals, imaging centers, and pharmaceutical partners globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersBedford, United States
HQ citystring
Bedford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices10 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
diagnostic imaging agents, radiopharmaceutical therapeutics, PET imaging agents, PSMA imaging diagnostics, nuclear medicine products
Industry2 codes
PRIMARYHLAIAGAA
Diagnostic Radiopharmaceuticals (SPECT/PET Tracers)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Radiopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Product Sales - Diagnostic Imaging Agents
TypeOne Time License
Description

Lantheus generates revenue primarily through the sale of FDA-approved diagnostic imaging agents including PYLARIFY (piflufolastat F 18), DEFINITY, and Neuraceq. These radiopharmaceutical products are sold to hospitals, imaging centers, and healthcare providers for diagnostic procedures.

in.investing.com
2Therapeutic Radiopharmaceuticals
TypeOne Time License
Description

Revenue from co-commercialization and future sales of therapeutic radiopharmaceutical products including PNT2003 (Lutetium Lu 177 Dotatate) and potential future therapeutic candidates.

seekingalpha.com
3Contract Manufacturing / CDMO Services
TypeProfessional Services
Description

Revenue from manufacturing services through Evergreen Theragnostics CDMO capabilities, providing radiopharmaceutical manufacturing services to pharmaceutical partners.

investor.lantheus.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 9 records shown
1PYLARIFY
Description

PSMA PET imaging agent for prostate cancer detection

lantheus.com
+8 more records
Core offering1 text field

Lantheus develops, manufactures, and commercializes diagnostic imaging agents and therapeutic radiopharmaceuticals for oncology, neurology, and cardiology. The commercial portfolio centers on PYLARIFY (PSMA PET imaging for prostate cancer) and DEFINITY (ultrasound contrast agent), with recent launches including PYLARIFY TruVu and PNT2003, plus Neuraceq for Alzheimer's imaging. The company also offers CDMO services through its Evergreen Theragnostics subsidiary.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • PYLARIFY showed strong Q4 2025 performance with over $240 million in quarterly revenue despite competitive pressures.
+2 more records
Product overview1 text field

Lantheus Holdings is a radiopharmaceutical-focused company offering a portfolio of diagnostic imaging agents and radiopharmaceutical products. The core portfolio includes PYLARIFY (PSMA PET for prostate cancer) and DEFINITY (ultrasound contrast agent), supplemented by the acquired Neuraceq amyloid imaging agent. Key pipeline products include PYLARIFY TruVu (higher-throughput reformulation), PNT2003 (Lutetium-based neuroendocrine tumor treatment), MK-6240 (Tau PET for Alzheimer's), LNTH-2501/OCTEVY (neuroendocrine tumor diagnostic), and LNTH-2513 (DVT imaging). The company is pivoting toward PET radiodiagnostics while divesting SPECT assets, and offers AI-enabled analysis tools through its PYLARIFY AI platform.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

SHINE Technologies acquired Lantheus's SPECT isotope distribution business in January 2026 for approximately $240 million in Series E funding led by Dr. Patrick Soon-Shiong. The transaction includes supply agreements for Lu-177 isotopes. SHINE also raised $240 million in Series E with Dr. Patrick Soon-Shiong joining the board.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Development opportunities in cardiac imaging agents partnered with GE Healthcare. Lantheus is pursuing cardiac imaging applications leveraging its radiopharmaceutical platform.

3Academic and Pharmaceutical Partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Pharma Solutions partnerships supporting global clinical trials across oncology, neurology and cardiology. Lantheus provides radiopharmaceutical manufacturing and clinical trial support services to pharmaceutical companies.

lantheus.com
4Enigma Biomedical USA
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-01
Description

Enigma Biomedical USA announced FDA acceptance of NDA for florquinitau F-18 (MK-6240), a Tau PET radiodiagnostic for Alzheimer's disease, with target action date of August 13, 2026. Lantheus holds commercial rights to MK-6240 following its 2023 acquisition of Cerveau Technologies.

biospace.com
5Life Healthcare (Life Molecular Imaging)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-01
Description

Lantheus acquired Life Molecular Imaging (LMI) unit from South African healthcare group Life Healthcare in 2025. The acquisition included an upfront payment and potential milestone payments. LMI brings Neuraceq (amyloid-beta PET imaging agent) and additional pipeline assets for Alzheimer's diagnostics.

businesstech.co.za
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Lantheus acquired Evergreen Theragnostics for $250 million upfront with potential additional milestone payments of up to $752.5 million. Evergreen provides CDMO (contract development and manufacturing organization) services for radiopharmaceuticals, expanding Lantheus's manufacturing capabilities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-02-06
Description

Lantheus acquired Cerveau Technologies, a Knoxville-based developer of PET imaging agents including MK-6240, a tau-detecting agent for Alzheimer's disease. MK-6240 is in clinical development and being used in over 60 trials worldwide by more than 16 pharmaceutical companies. Deal involved upfront, milestone, and royalty arrangements.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-12-01
Description

Lantheus licensed exclusive worldwide rights to PNT2003 (Lutetium Lu 177 Dotatate) from POINT Biopharma Global in December 2022. POINT Biopharma was subsequently acquired by Eli Lilly and Company in December 2023, with Lantheus maintaining its licensing agreement.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Novartis owns Advanced Accelerator Applications and markets LUTATHERA and Pluvicto, the direct competitive anchors in the neuroendocrine tumor and PSMA-lutetium therapeutic spaces. Lantheus's PNT2003 is positioned as a radioequivalent to LUTATHERA, making Novartis its closest head-to-head peer in radiopharmaceuticals.

TypeDirect peer
Description

Telix markets Illuccix (Ga-68 PSMA-11), the principal US competitor to Lantheus's PYLARIFY in prostate cancer PSMA PET imaging. Telix also has a broader theranostic pipeline including TLX591 (177Lu-rosopatamab) and is a direct competitor in multiple radiopharmaceutical indications.

TypeDirect peer
Description

PE-backed Curium is a vertically integrated radiopharmaceutical manufacturer with a portfolio of diagnostic and therapeutic products across SPECT, PET, and oncology. It is currently the would-be acquirer of Lantheus at a ~$7B valuation and competes in radiopharmacy, neuroendocrine, and prostate cancer imaging.

TypeDirect peer
Description

Bracco is a privately held diagnostic imaging company with a portfolio of contrast agents and emerging radiopharmaceuticals, including partnerships in PSMA and oncology imaging. It directly competes with Lantheus in contrast-enhanced ultrasound (vs. DEFINITY) and is expanding into molecular imaging.

TypeBroad incumbent
Description

Bayer historically operated a major diagnostic imaging business (Piramal/Life Molecular Imaging lineage) and retains broader pharma scale. Lantheus's Head of R&D, Ludger Dinkelborg, came from Bayer, and Bayer's Molecular Imaging division historically competed with Neuraceq's predecessor products.

TypeBroad incumbent
Description

GE HealthCare is a major medical imaging equipment vendor with growing pharmaceutical diagnostics and radiopharmaceutical partnerships. Lantheus has an active cardiac imaging partnership with GE HealthCare, and the two compete and collaborate across the molecular imaging value chain.

TypeBroad incumbent
Description

Siemens Healthineers is a global medical imaging equipment leader whose PET/CT scanners and software platforms underpin nuclear medicine workflows. As a broad incumbent, it competes with Lantheus-adjacent imaging informatics and serves as a key channel for adoption of PSMA, amyloid, and tau PET imaging.

TypeBroad incumbent
Description

Philips is a major medical imaging and healthcare IT incumbent with PET and SPECT scanner systems that enable the diagnostic workflows in which Lantheus's radiopharmaceuticals are used. As a broad incumbent, Philips competes and partners across the molecular imaging ecosystem.

TypeOthers
Description

Lilly acquired POINT Biopharma Global (December 2023), which originally licensed PNT2003 to Lantheus. Lilly is the upstream originator/partner for one of Lantheus's key therapeutic assets and is a peer via that licensing arrangement rather than direct product overlap.

TypeEmerging player
Description

ITM is a German privately held radiopharmaceutical company developing both diagnostic and therapeutic radionuclide-based products in oncology, including Lu-177-based candidates. It competes with Lantheus in targeted radionuclide therapy and represents an emerging European peer in the space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles24 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lantheus Holdings

Radiopharmaceuticalslantheus.com

Lantheus Holdings is a publicly traded radiopharmaceutical company that develops and commercializes diagnostic imaging agents and therapeutic radiopharmaceuticals for oncology, neurology, and cardiology, serving hospitals, imaging centers, and pharmaceutical partners globally.

What Lantheus Holdings does

Lantheus Holdings is a Bedford, Massachusetts-based radiopharmaceutical company that develops, manufactures, and commercializes diagnostic imaging agents and therapeutic radiopharmaceuticals. Founded in 1956 (originally as New England Nuclear Corporation), the company is publicly traded on NASDAQ under the ticker LNTH and operates with over 1,000 employees across the U.S., Canada, Germany, Sweden, Switzerland, and the U.K. Its core technology combines radioactive isotopes with targeting molecules to produce PET and SPECT imaging agents, as well as Lu-177-based therapeutic radiopharmaceuticals.

The commercial portfolio centers on PYLARIFY (piflufolastat F 18), the leading PSMA PET imaging agent for prostate cancer in the U.S. (generating over $240 million in Q4 2025 revenue), and DEFINITY, an ultrasound contrast agent for echocardiography. The pipeline includes the newly approved PYLARIFY TruVu (higher-throughput reformulation), PNT2003 (Lutetium Lu 177 Dotatate for GEP-NETs, tentative FDA approval), MK-6240 (Tau PET for Alzheimer's, August 2026 PDUFA), LNTH-2501/OCTEVY (Ga 68 edotreotide for neuroendocrine tumors, currently subject to an FDA Complete Response Letter), and LNTH-2513/18F-GP1 (DVT imaging). The company has built an integrated theranostics platform spanning diagnostic imaging and therapeutic radiopharmaceuticals, supplemented by AI-enabled image analysis tools (PYLARIFY AI, CURE8) and a CDMO business acquired through Evergreen Theragnostics.

Revenue is generated primarily through one-time product sales of FDA-approved diagnostic and therapeutic radiopharmaceuticals to hospitals, imaging centers, and healthcare providers, distributed via direct sales, an e-commerce portal, and international distributors. The company also derives revenue from Pharma Solutions partnerships providing clinical trial manufacturing support to pharmaceutical companies. In 2026 the company is weighing an unsolicited ~$7 billion takeover offer from Curium Pharma while operating under Interim CEO Mary Anne Heino following the end-of-2025 retirement of CEO Brian Markison and departure of President Paul Blanchfield.

Lantheus Holdings firmographics

Firmographics
Name
Lantheus Holdings
Legal name
Lantheus Holdings, Inc.
Website
https://lantheus.com
Company type
Public
Founded year
1956
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Lantheus Holdings is a publicly traded radiopharmaceutical company that develops and commercializes diagnostic imaging agents and therapeutic radiopharmaceuticals for oncology, neurology, and cardiology, serving hospitals, imaging centers, and pharmaceutical partners globally.
Ownership category
akta.pro rank

Lantheus Holdings industry classification

Industry
Product category
Radiopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAGAA
Diagnostic Radiopharmaceuticals (SPECT/PET Tracers)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Diagnostic imaging agents
  • Radiopharmaceutical therapeutics
  • PET imaging agents
  • PSMA imaging diagnostics
  • Nuclear medicine products

Where Lantheus Holdings is headquartered

Location

Headquarters

HQ city
Bedford
HQ country
United States
HQ region
North America

Offices10 records

Markets served

Lantheus Holdings business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain

Revenue model

  1. Product Sales - Diagnostic Imaging Agents: Lantheus generates revenue primarily through the sale of FDA-approved diagnostic imaging agents including PYLARIFY (piflufolastat F 18), DEFINITY, and Neuraceq. These radiopharmaceutical products are sold to hospitals, imaging centers, and healthcare providers for diagnostic procedures.
  2. Therapeutic Radiopharmaceuticals: Revenue from co-commercialization and future sales of therapeutic radiopharmaceutical products including PNT2003 (Lutetium Lu 177 Dotatate) and potential future therapeutic candidates.
  3. Contract Manufacturing / CDMO Services: Revenue from manufacturing services through Evergreen Theragnostics CDMO capabilities, providing radiopharmaceutical manufacturing services to pharmaceutical partners.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Lantheus Holdings product offering

Product offering

Core offering

Lantheus develops, manufactures, and commercializes diagnostic imaging agents and therapeutic radiopharmaceuticals for oncology, neurology, and cardiology. The commercial portfolio centers on PYLARIFY (PSMA PET imaging for prostate cancer) and DEFINITY (ultrasound contrast agent), with recent launches including PYLARIFY TruVu and PNT2003, plus Neuraceq for Alzheimer's imaging. The company also offers CDMO services through its Evergreen Theragnostics subsidiary.

Product overview

Lantheus Holdings is a radiopharmaceutical-focused company offering a portfolio of diagnostic imaging agents and radiopharmaceutical products. The core portfolio includes PYLARIFY (PSMA PET for prostate cancer) and DEFINITY (ultrasound contrast agent), supplemented by the acquired Neuraceq amyloid imaging agent. Key pipeline products include PYLARIFY TruVu (higher-throughput reformulation), PNT2003 (Lutetium-based neuroendocrine tumor treatment), MK-6240 (Tau PET for Alzheimer's), LNTH-2501/OCTEVY (neuroendocrine tumor diagnostic), and LNTH-2513 (DVT imaging). The company is pivoting toward PET radiodiagnostics while divesting SPECT assets, and offers AI-enabled analysis tools through its PYLARIFY AI platform.

Differentiator

Problem solved

Functional benefit

Brands

  • PYLARIFY: PSMA PET imaging agent for prostate cancer detection
  • PYLARIFY TruVu
  • DEFINITY
  • NeuraCeq
  • PYLARIFY AI
  • CURE8
  • PNT2003
  • LNTH-2501 (OCTEVY)
  • LNTH-2513 (18F-GP1)

Quantifiable outcome

  • PYLARIFY showed strong Q4 2025 performance with over $240 million in quarterly revenue despite competitive pressures.
  • +2 more outcomes

Companies that use Lantheus Holdings

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Lantheus Holdings technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

Lantheus Holdings partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • SHINE TechnologiescoreStrategic or Co-development Partner · 1 January 2026SHINE Technologies acquired Lantheus's SPECT isotope distribution business in January 2026 for approximately $240 million in Series E funding led by Dr. Patrick Soon-Shiong. The transaction includes supply agreements for Lu-177 isotopes. SHINE also raised $240 million in Series E with Dr. Patrick Soon-Shiong joining the board.
  • GE HealthcareminorStrategic or Co-development Partner · 1 January 2026Development opportunities in cardiac imaging agents partnered with GE Healthcare. Lantheus is pursuing cardiac imaging applications leveraging its radiopharmaceutical platform.
  • Academic and Pharmaceutical PartnersminorStrategic or Co-development Partner · 1 January 2026Pharma Solutions partnerships supporting global clinical trials across oncology, neurology and cardiology. Lantheus provides radiopharmaceutical manufacturing and clinical trial support services to pharmaceutical companies.
  • Enigma Biomedical USAcoreTechnology or Integration · 1 October 2025Enigma Biomedical USA announced FDA acceptance of NDA for florquinitau F-18 (MK-6240), a Tau PET radiodiagnostic for Alzheimer's disease, with target action date of August 13, 2026. Lantheus holds commercial rights to MK-6240 following its 2023 acquisition of Cerveau Technologies.
  • Life Healthcare (Life Molecular Imaging)coreStrategic or Co-development Partner · 1 July 2025Lantheus acquired Life Molecular Imaging (LMI) unit from South African healthcare group Life Healthcare in 2025. The acquisition included an upfront payment and potential milestone payments. LMI brings Neuraceq (amyloid-beta PET imaging agent) and additional pipeline assets for Alzheimer's diagnostics.
  • Evergreen TheragnosticscoreStrategic or Co-development Partner · 1 January 2025Lantheus acquired Evergreen Theragnostics for $250 million upfront with potential additional milestone payments of up to $752.5 million. Evergreen provides CDMO (contract development and manufacturing organization) services for radiopharmaceuticals, expanding Lantheus's manufacturing capabilities.
  • Cerveau TechnologiescoreTechnology or Integration · 6 February 2023Lantheus acquired Cerveau Technologies, a Knoxville-based developer of PET imaging agents including MK-6240, a tau-detecting agent for Alzheimer's disease. MK-6240 is in clinical development and being used in over 60 trials worldwide by more than 16 pharmaceutical companies. Deal involved upfront, milestone, and royalty arrangements.
  • POINT Biopharma Global, Inc.coreTechnology or Integration · 1 December 2022Lantheus licensed exclusive worldwide rights to PNT2003 (Lutetium Lu 177 Dotatate) from POINT Biopharma Global in December 2022. POINT Biopharma was subsequently acquired by Eli Lilly and Company in December 2023, with Lantheus maintaining its licensing agreement.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Lantheus Holdings competitors and assessment

Company assessment

Direct peers

  • Novartis: Novartis owns Advanced Accelerator Applications and markets LUTATHERA and Pluvicto, the direct competitive anchors in the neuroendocrine tumor and PSMA-lutetium therapeutic spaces. Lantheus's PNT2003 is positioned as a radioequivalent to LUTATHERA, making Novartis its closest head-to-head peer in radiopharmaceuticals.
  • Telix Pharmaceuticals: Telix markets Illuccix (Ga-68 PSMA-11), the principal US competitor to Lantheus's PYLARIFY in prostate cancer PSMA PET imaging. Telix also has a broader theranostic pipeline including TLX591 (177Lu-rosopatamab) and is a direct competitor in multiple radiopharmaceutical indications.
  • Curium Pharma: PE-backed Curium is a vertically integrated radiopharmaceutical manufacturer with a portfolio of diagnostic and therapeutic products across SPECT, PET, and oncology. It is currently the would-be acquirer of Lantheus at a ~$7B valuation and competes in radiopharmacy, neuroendocrine, and prostate cancer imaging.
  • Bracco Imaging: Bracco is a privately held diagnostic imaging company with a portfolio of contrast agents and emerging radiopharmaceuticals, including partnerships in PSMA and oncology imaging. It directly competes with Lantheus in contrast-enhanced ultrasound (vs. DEFINITY) and is expanding into molecular imaging.

Broad incumbents

  • Bayer: Bayer historically operated a major diagnostic imaging business (Piramal/Life Molecular Imaging lineage) and retains broader pharma scale. Lantheus's Head of R&D, Ludger Dinkelborg, came from Bayer, and Bayer's Molecular Imaging division historically competed with Neuraceq's predecessor products.
  • GE HealthCare: GE HealthCare is a major medical imaging equipment vendor with growing pharmaceutical diagnostics and radiopharmaceutical partnerships. Lantheus has an active cardiac imaging partnership with GE HealthCare, and the two compete and collaborate across the molecular imaging value chain.
  • Siemens Healthineers: Siemens Healthineers is a global medical imaging equipment leader whose PET/CT scanners and software platforms underpin nuclear medicine workflows. As a broad incumbent, it competes with Lantheus-adjacent imaging informatics and serves as a key channel for adoption of PSMA, amyloid, and tau PET imaging.
  • Philips: Philips is a major medical imaging and healthcare IT incumbent with PET and SPECT scanner systems that enable the diagnostic workflows in which Lantheus's radiopharmaceuticals are used. As a broad incumbent, Philips competes and partners across the molecular imaging ecosystem.

Others

  • Eli Lilly: Lilly acquired POINT Biopharma Global (December 2023), which originally licensed PNT2003 to Lantheus. Lilly is the upstream originator/partner for one of Lantheus's key therapeutic assets and is a peer via that licensing arrangement rather than direct product overlap.

Emerging players

  • ITM (Isotope Technologies Munich): ITM is a German privately held radiopharmaceutical company developing both diagnostic and therapeutic radionuclide-based products in oncology, including Lu-177-based candidates. It competes with Lantheus in targeted radionuclide therapy and represents an emerging European peer in the space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Lantheus Holdings social profiles

Digital presence

Lantheus Holdings financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lantheus Holdings leadership team

Management profile

Number of profiles

Profiles24 records

Lantheus Holdings subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Lantheus Holdings funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lantheus Holdings M&A and investment

M&A and investment

M&A5 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lantheus Holdings

What does Lantheus Holdings do?

Lantheus develops, manufactures, and commercializes diagnostic imaging agents and therapeutic radiopharmaceuticals for oncology, neurology, and cardiology. The commercial portfolio centers on PYLARIFY (PSMA PET imaging for prostate cancer) and DEFINITY (ultrasound contrast agent), with recent launches including PYLARIFY TruVu and PNT2003, plus Neuraceq for Alzheimer's imaging. The company also offers CDMO services through its Evergreen Theragnostics subsidiary.

Is Lantheus Holdings a public or private company?

Lantheus Holdings is a public company. It is classified as public and is currently operating.

When was Lantheus Holdings founded?

Lantheus Holdings was founded in 1956. It employs 1,001 to 5,000 people.

Where is Lantheus Holdings based?

Lantheus Holdings is headquartered in Bedford, United States, in the North America region.

How does Lantheus Holdings make money?

Three revenue lines are on record. Product Sales - Diagnostic Imaging Agents are the primary driver. The others are therapeutic Radiopharmaceuticals and contract Manufacturing / CDMO Services.

Who are Lantheus Holdings's main competitors?

Direct peers on record are Novartis, Telix Pharmaceuticals, Curium Pharma and Bracco Imaging. Broad incumbents are Bayer, GE HealthCare, Siemens Healthineers and Philips. Eli Lilly is listed as an others. ITM (Isotope Technologies Munich) is listed as an emerging player.

Does Lantheus Holdings have an API?

No public API is recorded for Lantheus Holdings.

What industry is Lantheus Holdings in?

Lantheus Holdings's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAA, Diagnostic Radiopharmaceuticals (SPECT/PET Tracers), with a secondary code of HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy). Its NAICS code is 325414 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpacePharmaLogic buys Lantheus plant to build transatlantic radiopharmaceutical CDMOPharmaLogic agreed to buy Lantheus's radiopharmaceutical CDMO and a New Jersey plant for an undisclosed sum. The Springfield facility, completed in 2021, will support transatlantic production, and employees will join Agilera Pharma. Lantheus is selling the assets while pursuing its merger with Curium, closing in 2027.Endpoints NewsMerck KGaA's writedown over Lonza deal; PharmaLogic buys Lantheus' CDMO businessMerck KGaA reported a €366 million impairment loss on its business sale to Lonza. PharmaLogic acquired Lantheus' CDMO business. No further details were disclosed.Business & FinancialRadiopharmaceuticals Market To Reach USD 15.21 Billion By 2035 As Radioligand Therapy Moves Earlier In Cancer Care And Curiumlantheus Reshapes The Competitive MapThe radiopharmaceuticals market is projected to grow from USD 7.51 billion in 2025 to USD 15.21 billion by 2035, with a 7.31% CAGR. Diagnostics and oncology lead, while therapeutics grow fastest, and Curium agreed to acquire Lantheus for up to USD 8 billion.FiercePharmaRadiopharma player PharmaLogic snaps up Lantheus' CDMO business, plant as Curium acquisition advancesPharmaLogic agreed to buy Lantheus' CDMO business and its Springfield, New Jersey plant for an undisclosed sum. The deal will add capacity to Agilera, PharmaLogic's therapeutic CDMO unit, as Curium's $8 billion acquisition of Lantheus closes.American Banking and Market NewsLantheus Holdings, Inc. $LNTH Shares Sold by Ashton Thomas Private Wealth LLCAshton Thomas Private Wealth LLC reduced its Lantheus Holdings stake by 59.3% in Q3, selling 8,852 shares and leaving with 6,063 shares worth $603,000. Other institutional investors also adjusted positions, while analysts rate the stock a Hold with a consensus target of $107.44.Pulse 2.0PharmaLogic: Lantheus CDMO Acquisition Expands Radiopharmaceutical Manufacturing Capacity In New JerseyPharmaLogic agreed to acquire Lantheus' contract development and manufacturing business and its Springfield, New Jersey facility, expanding its U.S. radiopharmaceutical manufacturing. The deal includes a long-term supply arrangement for lutetium Lu 177 dotatate, and the Springfield site will join Agilera. The transaction is subject to regulatory reviews and customary closing requirements.MarketWatchPharmaLogic Agrees to Buy Lantheus' CDMO Business, N.J. FacilityPharmaLogic agreed to acquire Lantheus Holdings' contract development and manufacturing organization business and a Springfield, N.J. facility. The deal includes a long-term agreement for Agilera to supply lutetium Lu 177 dotatate to Lantheus. Financial terms were not disclosed.Business & FinancialLantheus Announces Presentation Of Data At The 2026 Clinical Trials On Alzheimer's Disease Annual MeetingLantheus will present two poster presentations at the 2026 Clinical Trials on Alzheimer's Disease Annual Meeting on November 16-17. The posters cover tau pathology detection with florquinitau F 18 PET and age-independent astrocytic MAO-B imaging with 18F-FDED PET.MarketBeatLantheus (LNTH) Expected to Announce Earnings on ThursdayLantheus is expected to report Q3 2026 earnings on Thursday, November 5th, with analysts projecting EPS of $1.26 and revenue of $360.82 million. The company's last quarterly EPS was $1.55, beating estimates, and revenue was $388.18 million. Analysts have an average rating of Hold with a target price of $107.44.MarketBeatLantheus Holdings, Inc. (NASDAQ:LNTH) Stock Now Rated "Hold" by Sell-Side AnalystsAnalysts rate Lantheus Holdings stock as a Hold, with an average 12-month price target of $107.44. The company reported Q2 EPS of $1.55, beating estimates, and revenue of $388.18 million, up 2.7% year-over-year. Institutional investors own 99.06% of the stock.